MedTrace Logo

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

NCT07018037 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-06-12

No results posted yet for this study

Summary

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Conditions

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-29
Primary Completion
2026-01-29
Completion
2027-01-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07018037 on ClinicalTrials.gov